Visualize cervical cancer and r/mCC burden across the US

Cervical Cancer Geographical Burden Analyzer

As the fourth most frequently diagnosed and fourth most deadly cancer in women worldwide, cervical cancer carries a high disease burden in the US (1). While screening has improved the early detection of cervical cancer, up to 16% initially present with metastatic disease (2), whose 5-year survival rate is dismal at 17% (3). Of those whose cancer is detected in earlier stages, 15-61% go on to develop metastatic cervical cancer within the first 2 years following completion of initial treatment (2).

Using MarketScan™ claims data, Value Analytics Labs collaborated with the Seagen HEOR team to design and conduct a real-world evidence study to understand the predictors of treatment continuation and the geographical differences in cervical cancer burden. Our findings were incorporated into the Cervical Cancer Geographical Burden Analyzer, an open access, web-based, interactive tool to visualize geographical areas in the US where cervical cancer education or healthcare resource needs are high.

The tool (4) and the study findings (5) that support the tool were presented at the 2022 American Society of Clinical Oncology’s annual meeting in Chicago.

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424.
  2. Insititute NC. SEER Cancer Stat Facts: Cervical Cancer. 2022 https://seer.cancer.gov/statfacts/html/cervix.html. Accessed May 20, 2022
  3. Pfaendler KS, Tewari KS. Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol. 2016;214(1):22-30.
  4. Castellano T, Washington C, Moore KN, Yildiz Y, Surinach A, Ting J, Chhatwal J, et al. Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer. Journal of Clinical Oncology 2022;40:5523-5523.
  5. Sonawane K, Castellano T, Washington C, Ayer T, Surinach A, Kirshner C, Ting J, et al. Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis. Journal of Clinical Oncology 2022;40:5532- 5532

CONNECT WITH US

Our team is known for excellence and developing customized end-to-end solutions that meet our esteemed clients’ needs and provide 100% satisfaction.

©2022 Value Analytics Labs. All rights reserved | Terms of Service | Privacy Policy | Design by 9piksel